Regulatory News:
The Annual General Meeting and Extraordinary General Meeting
will be held at MedinCell's (Paris:MEDCL) headquarters (3 rue des
Frères Lumière, 34830 Jacou, France) on Tuesday, September 12,
2023, at 6.00 p.m., CEST.
All shareholders of the company are invited to attend the
meeting or to follow it live on the company’s website via the link
https://www.medincell.com/en/investisseurs/#events
The secure remote voting system via the Votaccess platform will
be open from Tuesday, August 22, 2023, at 10:00 a.m. to Monday,
September 11, 2023, at 3:00 p.m., CEST.
MedinCell will hold a video conference on Tuesday, September
5, 2023, at 6 p.m.
to present the resolutions of the Annual General Meeting and
answer questions from shareholders.
Connection link:
https://www.medincell.com/en/investisseurs/#events
An internet connection will be required to access the conference
and ask questions.
Terms and conditions of
participation
MedinCell strongly encourages all its shareholders to exercise
their voting rights, either by remote voting, which must be cast
before the General Meeting, or during the General Meeting for
shareholders present in person.
MedinCell shareholders who wish to vote by remotely may do so
before the General Meeting as follows:
- Internet voting will be available and
should be used as a priority: the secure voting platform Votaccess
will be open from Tuesday, August 22, 2023, at 10 a.m. to Monday,
September 11, 2023, at 3 p.m., Paris time. Shareholders will be
able to vote by Internet or give their proxy to the Chairman of the
Meeting until the day before the General Meeting (i.e., Monday,
September 11, 2023) at 3 p.m., Paris time.
- Shareholders may also vote by post
following the procedures set out in the notice of meeting published
in the Bulletin des Annonces Légales et Obligatoires on August 4th,
2023. The deadline for receipt of forms is September 8, 2023. If a
proxy is given to a natural or legal person, the proxy will send
their voting instructions by e-mail to the following address:
ct-mandataires-assemblees@uptevia.com. The deadline for
receipt is September 11, 2023, at 3:00 p.m.
All shareholders may send their written questions, either by
registered letter with a return receipt requested addressed to the
Chairman of the Executive Board at the company’s registered office
(3 rue des Frères Lumière, 34830 Jacou) or by e-mail to
legal@medincell.com, no later than the fourth business day
preceding the date of the Shareholders’ Meeting (i.e., September 6,
2023). A certificate of account registration must accompany the
questions.
As the company cannot control the identity of the persons
attending the meeting remotely, only the persons physically present
will be able to ask questions during the General Meeting.
Availability of documents relating to
the General Meeting
The notice of meeting, valid as notice of convocation, which
includes the agenda, draft resolutions, and the main terms of
participation and voting at the Shareholders' Meeting, was
published in the Bulletin des Annonces Légales et Obligatoires N°.
93 of August 4th, 2023.
The preparatory documents and information relating to this
General Meeting will be made available to shareholders under the
legal and regulatory conditions and will be available on the
website: https://www.medincell.com/en/investisseurs/#meeting_
Shareholders are invited to consult the section dedicated to the
General Meeting on the Company's website:
https://www.medincell.com/en/investors/#meeting_
About MedinCell
MedinCell is a commercial-stage technology pharmaceutical
company developing long-acting injectable drugs in many therapeutic
areas. Our innovative treatments aim to guarantee compliance with
medical prescriptions, to improve the effectiveness and
accessibility of medicines, and to reduce their environmental
footprint. They combine already known and used active ingredients
with our proprietary BEPO® technology which controls the delivery
of a drug at a therapeutic level for several days, weeks or months
from the subcutaneous or local injection of a simple deposit of a
few millimeters, entirely bioresorbable. The first treatment based
on BEPO technology, intended for the treatment of schizophrenia,
was approved by the FDA in April 2023, and is now distributed in
the United States by Teva under the name UZEDY™ (BEPO technology is
licensed to Teva under the name SteadyTeq™).
We collaborate with leading pharmaceutical companies and
foundations to improve global health through new treatment options.
Based in Montpellier, MedinCell currently employs more than 140
people representing more than 25 different nationalities.
UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230821385449/en/
MedinCell
David Heuzé Head of Communications
david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Louis-Victor Delouvrier/Alban Dufumier Investor
Relations medincell@newcap.eu +33 (0)1 44 71 94 94
NewCap Nicolas Merigeau Media Relations
medincell@newcap.eu +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024